We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.
|Journal||Clinics and Research in Hepatology and Gastroenterology|
|Publication status||Published - 1 Aug 2022|
Bibliographical noteAcknowledgements: We would like to thank the patient of this case report. She gave us permission to write down her disease course and she was very helpful in sharing her patient history. We did not receive any funding for this study. We would like to thank Kabir Paul Ravindra for checking English grammar and syntax.
Publisher Copyright: © 2022 The Author(s)